Influence Of Lipid Levels Research Articles

Influence of lipid levels in the diet on the degree of absorption of minerals in the body of broiler chickens

Relevance. Precocious modern crosses of broiler chickens need a high-energy diet. Vegetable oils, being a concentrated source of energy, cover the necessary energy demand. At the same time, the amount and type of fat used in the diet to increase energy value can affect the metabolism of trace elements. Thus, there may be a relationship between the concentration and type of lipids in the diet and the metabolism of trace elements.The purpose of the study was to evaluate the effect of various doses of sunflower oil in the diet on minerals in the body of broiler chickens.Methods. Experimental studies to assess the effect of a high-energy diet on the mineral status of the body were conducted in three groups of broiler chickens of the Arbor Acres cross, formed by the method of pairs of analogues (n = 35). The basic diet was adjusted for metabolic energy. The subject of research is the mineral composition of the liver and bone tissue, as well as biochemical and morphological parameters of blood.Results. Based on research, it has been established that feeding broiler chickens is highly co-energy diet causes changes in the metabolism of certain trace elements and leads to to malabsorption. In the liver, blood serum and bone tissue, the studied elements (Fe, Cu and Zn) decreased in the experiment. The result obtained requires further research and indicates on the possible need for correction of mineral nutrition in high-energy diets.

Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome

BackgroundIntensive statin therapy decreases mortality and incidence of coronary events in patients after acute coronary syndrome (ACS). Recently it has been reported that spontaneous lipid levels remain clinically stable during ACS. The immediate influence of lipid levels by high-dose statin therapy initiated at admission in ACS patients is, however, not clear.MethodsWe have analyzed a group of 114 patients with ACS (mean age 63.7; females 25.4%). Atorvastatin 80 mg was administered at admission and then once daily for the rest of hospitalization. The levels of total cholesterol (TC), LDL-cholesterol (LDL), HDL-cholesterol (HDL), and triglycerides (TG) were measured at admission (D0), and then every morning of hospitalization (D1, D2).ResultsThe mean entry values (D0) of TC, LDL, HDL and TG (in mmol/L) were 5.24, 3.26, 1.07 and 1.31, respectively. The therapy with atorvastatin 80 mg resulted in a decrease of TC levels in the first morning (D1) by 6.1% and in the second morning (D2) by 13.2% (p < 0.001 for all comparisons with the entry value D0); LDL was decreased by 5.8% (D1) and 15.6% (D2) (p < 0.001 vs. D0); the level of HDL was decreased by 7.5% (D1) and 12.1% (D2) (p < 0.001 vs. D0). In contrast, the TG level was higher in the first morning (D1) by 20.6% and in the following morning (D2) by 25.5% (p < 0.05 vs. D0).ConclusionsWe have shown that intensive statin therapy started at admission in ACS patients has a highly significant, immediate effect on all monitored lipid levels. Since TC and LDL levels were decreased as predicted, reduction in HDL and increase in TG levels suggest a different acute effect of high-dose statin on lipid levels in comparison with long-term treatment of ACS patients.

Effects of adjuvant aromatase inhibitor therapy on lipid profiles

How aromatase inhibitors affect lipids is of great interest. Compared with tamoxifen, adjuvant anastrozole and letrozole are associated with increased incidences of hypercholesterolemia, while similar data are lacking for exemestane in the adjuvant setting. No significant differences in lipid profiles occurred with extended adjuvant exemestane compared with placebo, but total cholesterol and low-density lipoprotein levels increased significantly above baseline in both groups over 6 months. Likewise, no significant differences in hypercholesterolemia rates occurred between extended adjuvant letrozole and placebo. A lipid substudy further confirmed that letrozole did not significantly alter serum lipids for 36 months compared with placebo. Thus, although aromatase inhibitors lack the lipid-lowering properties of tamoxifen, no significant worsening of lipid levels occurs with their use. Patients would benefit from lifestyle changes and routine monitoring of serum lipids. Breast cancer therapy trials often report serum lipid parameters, but assessing the quality and overall significance of the data can be difficult. Methodology of data collection varies among trials and the concomitant use of lipid-modifying medication is often not reported. This review discusses the current understanding of the influence of lipid levels on cardiovascular risk in women and presents key findings on the effects of adjuvant aromatase inhibitor therapy on lipid profiles.